systematic_review
2017
High Quality
S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders: A Clinician-Oriented Review of Research
Sharma A, Gerbarg P, Bottiglieri T
Published in Journal of Clinical Psychiatry
Key Findings
SAMe, the active methionine metabolite, shows antidepressant efficacy as monotherapy and adjunct, with tolerability concerns in bipolar disorder.
Conclusions
Downstream metabolite, not methionine itself, carries the clinical evidence.
Limitations
Heterogeneous trials, varying formulations.
Supplements Studied
L-Methionine
Amino Acid
SAMe, the active metabolite of methionine, shows antidepressant efficacy as monotherapy and as an adjunct.
SAM-e
Compound
SAMe shows antidepressant signal mainly as adjunctive therapy, with a favourable safety profile aside from possible activation or mania risk in bipolar disorder.
Related Health Concerns
Study Details
Year:2017
Quality Score:7/10
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.